Stryker Fails To Convince FDA To Exempt Patient-Transport Devices
The US agency didn’t buy Stryker’s argument in its April petition that there is no data suggesting patient-transport devices have a history of false and misleading claims.
You may also be interested in...
A petition submitted to the US FDA seeks to exempt class II powered patient-transport devices from premarket notification requirements.
US Medicare has granted a new technology add-on payment (NTAP) for an innovative technology designed to treat adult spinal deformity.
Agency issued an emergency use authorization to Labcorp for its OTC that detects COVID-19, flu and respiratory syncytial virus.